Alpha polylactate

Synopsis

Alpha-L-Polylactate: A Comprehensive Reference

1. Identity, Chemical Nomenclature, and Commercial Form

Alpha-L-Polylactate (Alpha-L-PolyLactate™, also rendered as PolyLactate™ or Alpha-L-Polylactate™) is a proprietary, semi-synthetic nutritional ingredient based on the L-isomer of lactic acid (L-lactate). Polylactate (PL) is described in the peer-reviewed literature as a semi-soluble amino acid/lactate salt, marketed as a carbohydrate supplement purported to increase endurance. More specifically, the commercial formulation produced by CytoSport, Inc. is described as a non-acidic form of L-lactate ionically bound to L-arginine. The ingredient is characterized in product formulations as "our patented L-lactate formulation containing non-acidic L-lactate ionically bound to L-arginine."

Alpha-L-Polylactate is registered as a trademark (U.S. Trademark Registration Number 3263580, filed September 29, 2005, and registered July 10, 2007) by CytoSport, Inc., and is classified as a nutritional and dietary supplement ingredient. CytoSport does not sell it as a standalone supplement; the company owns the patent on it, making them the only ones with rights to it, and it is sold primarily as a component of their Cytomax formula.

The ingredient belongs to the broader chemical family of lactate-based compounds. Polylactate is described in peer-reviewed commentary as a combination of lactate and an amino acid. In its application within Cytomax, it is one of several carbohydrate sources, with the CytoMax formulation containing lactate-polymer, fructose, glucose, and glucose polymer, as distinct from competing products that contain only fructose and glucose.

1.1 Natural Basis: L-Lactate

The fundamental building block of Alpha-L-Polylactate is L-lactic acid (lactate), a metabolite that is naturally produced and consumed continuously in the human body. The metabolic significance of lactate was formally articulated in the Lactate Shuttle Hypothesis, proposed in 1985 by George Brooks of the University of California at Berkeley; in addition to its role as a fuel source predominantly in the muscles, heart, brain, and liver, the hypothesis also relates the role of lactate in redox signalling, gene expression, and lipolytic control. Prior to the lactate shuttle hypothesis, lactate had long been considered a mere byproduct resulting from glucose breakdown through glycolysis in times of anaerobic metabolism; as a means of regenerating oxidized NAD+, lactate dehydrogenase catalyzes the conversion of pyruvate to lactate in the cytosol, oxidizing NADH to NAD+.

1.2 Common Forms and Preparations

Alpha-L-Polylactate has been commercially available primarily as a component of powdered sports drink mixes. In ingredient lists, it appears within an "Advanced Carbohydrate System" blend alongside maltodextrin, crystalline fructose, and dextrose. The powdered drink mix form is designed to blend into water for consumption before, during, and after exercise. The recommended preparation involves mixing one to one and a half scoops into water per serving. Instructions indicate mixing one to one and a half scoops of Cytomax in 16 oz of water, beginning drinking 15–30 minutes into exercise, drinking 5 oz every 15 minutes, and after training slowly drinking another 16 oz over the next hour to aid recovery.

2. Traditional and Historical Use

Alpha-L-Polylactate is not a botanical or plant-derived traditional remedy. It is a proprietary synthetic/semi-synthetic ingredient with no documented history of use in pre-modern or indigenous medical traditions. It was developed and commercialized in the late 1980s by CytoSport, Inc. (creators of the Cytomax brand), whose product launch is documented as occurring around 1989. Cytomax has been described as a brand meeting the needs of performance-driven athletes since 1989.

The conceptual basis for the ingredient—the use of lactate as an ergogenic fuel—emerged from the laboratory research of Dr. George Brooks and colleagues at the University of California, Berkeley, whose work in the late 1980s and early 1990s characterized lactate as an active metabolic substrate rather than a simple waste product of anaerobic exercise. Decades of research in the area of metabolic adjustments to exercise led to the articulation of the "Lactate Shuttle" and the "Crossover Concept"; research on the Lactate Shuttle sought to elucidate the pathways and controls of lactate formation and removal before, during, and after exercise, involving studies on humans and animals, indirect calorimetry, isotope tracer technology, classical arterial-venous difference measurements, and muscle biopsies.

The ingredient's commercial history is therefore best understood as arising from the intersection of applied sports nutrition product development and emerging basic science research on lactate metabolism during the early 1990s.

3. Key Constituents and Active Compounds

3.1 L-Lactate as the Primary Active Moiety

The functionally active component of Alpha-L-Polylactate is the L-lactate anion. The specific rationale for using the L-isomer is its physiological relevance: L-lactate is the form naturally produced and metabolized in human muscle tissue. During physical exertion or moderate intensity exercise, lactate released from working muscle and other tissue beds is the primary fuel source for the heart, exiting the muscles through monocarboxylate transport protein (MCT); this evidence is supported by an increased amount of MCT shuttle proteins in the heart and muscle in direct proportion to exertion.

Working skeletal muscle both produces and uses lactate as a fuel, with much of the lactate formed in glycolytic fibres being taken up and oxidized in adjacent oxidative fibres; because it is more reduced than its keto-acid analogue, sequestration and oxidation of lactate to pyruvate affects cell redox state, both promoting energy flux and signalling cellular events.

3.2 Monocarboxylate Transporter (MCT) System

The cellular uptake of lactate (and thus the bioavailability of the active moiety in Alpha-L-Polylactate) depends on a family of specialized membrane proteins. Facilitated lactate transport is accomplished by a family of monocarboxylate transport proteins (MCTs) that are differentially expressed in cells and tissues. Lactate traverses membrane barriers by facilitated, carrier-mediated lactate anion and proton exchange involving a family of lactate/pyruvate monocarboxylate transport (MCT) proteins. MCT protein isoform expression patterns vary with muscle fiber type, and MCTs are expressed in tissues and cellular organelles that rapidly exchange lactate, including the brain.

The lactate shuttle is facilitated by membrane-bound monocarboxylate transporters (MCTs); in skeletal muscle, two distinct isoforms have been characterized—MCT-1 and MCT-4, each with different properties; training has been shown to have effects on the expression of MCTs resulting in more efficient use of lactate, particularly with respect to the clearance of lactate from the blood by increasing its uptake within cells.

3.3 The Polylactate Polymer Formulation and Its Rationale

The rationale for the polymer form (rather than simple sodium lactate) was to reduce the osmolality burden associated with lactate salt solutions. Researchers investigated polylactate as an alternative to simple lactate salts, noting that as the molecules were larger, the sodium load was much lower, and this would likely have positive effects on gastro-intestinal comfort. Simple sodium lactate solutions present significant osmolality challenges that limit practical use. The discomfort associated with sodium lactate supplementation is likely caused by the very high osmolality of these lactate salt solutions.

3.4 Proposed Mechanism: Proton Buffering

Beyond serving as an energy substrate, lactate in the Alpha-L-Polylactate formulation is hypothesized to exert a buffering action on intramuscular acidity—the accumulation of hydrogen ions (H+) that accompanies intense exercise and contributes to muscular fatigue. The lactate in CytoMax is able to stoichiometrically scavenge protons because the lactate anion is the salt of the acid; by scavenging protons, the lactate acts to spare bicarbonate during periods of high proton efflux from skeletal muscle or intense exercise; the disposal of exogenous lactate as lactic acid via oxidation or gluconeogenesis results in stoichiometric removal of protons (H+).

3.5 Proposed Mechanism: Gluconeogenic Precursor

A secondary proposed mechanism is lactate's role as a gluconeogenic substrate—its ability to be converted back to glucose in the liver, thereby supporting blood glucose maintenance during prolonged exercise. Fahey et al. found that in comparison to a glucose polymer, a PolyLactate-glucose polymer combination was able to maintain blood glucose at least as well as glucose polymer alone; this is likely due to the role of lactate in gluconeogenesis. Lactate could potentially function not only as a buffer-related substrate but also as a gluconeogenic precursor supporting carbohydrate availability during prolonged exercise.

3.6 Proposed Mechanism: Rapid Oxidation as Fuel

Isotopic tracer studies have confirmed that exogenous lactate is oxidized at substantially higher fractional rates than other carbohydrate substrates when consumed during exercise. One study reported the first finding of greater fractional oxidation of lactate in comparison to other carbohydrate energy substrates during exercise. Tracer data from the 2007 PLOS ONE cycling study demonstrated that cumulative recovery of tracer during exercise was 92% ± 5.3% for lactate in CytoMax vs. 25% ± 4.0% for glucose in either CytoMax or a comparator drink, and that by 60 min of exercise, ¹³CO₂ production from lactate was 33% greater than from glucose and 36% greater than from fructose.

4. Scientific Evidence by Area of Use

4.1 Exercise Endurance and Performance

4.1.1 Foundational Study: Fahey et al. (1991)

The earliest published human trial on polylactate as a sports drink ingredient is the Fahey et al. (1991) study, which provided the scientific foundation for subsequent commercial development. Five trained, fasted male cyclists rode a cycle ergometer three times at 50% of VO₂max for 180 minutes; using a balanced order, double-blind procedure, subjects were given either a solution containing polylactate (PL: 80% polylactate, 20% sodium lactate, in 7% solution with water), glucose polymer (GP: multidextrin in 7% solution with water), or control (water sweetened with aspartame) 5 minutes before exercise and at 20-minute intervals during exercise. In general, PL and GP rendered similar results except that pH and bicarbonate (HCO₃⁻) were higher in PL; there were no differences between treatments in perceived exertion, sodium, potassium, chloride, lactate, heart rate, oxygen consumption, rectal temperature, or selected skin temperatures. These data showed that polylactate may help maintain blood glucose and enhance blood buffering capacity during prolonged exercise and could be a useful component in an athletic fluid replacement beverage.

Limitations: The original study involved only five participants and did not include a meaningful performance outcome. The small sample and absence of direct performance (e.g., time-to-exhaustion or time-trial) measurement significantly constrain interpretation.

4.1.2 Swensen et al. (1994) — Null Endurance Outcome

A subsequent study by Swensen and colleagues at the University of Tennessee directly tested whether the addition of polylactate to a glucose polymer solution improved exercise endurance. The purpose was to determine if the addition of PL to a glucose polymer solution (GP) extends exercise time relative to a pure GP solution; in a double-blind and random crossover design, 5 subjects exercised twice to exhaustion at 70% of VO₂max. During the trials, they consumed GP or a GP/PL mixture at the rate of 0.3 g carbohydrate per kg of body weight in a 7% solution every 20 minutes until exhaustion; the GP/PL mixture contained 6.25 g GP to 0.75 g PL per 100 ml of water; importantly, the investigators noted that PL as supplied under experimental conditions produced severe gastro-intestinal efflux in concentrations ≥ 2.5%, while PL was tolerable in concentrations ≤ [a lower threshold]. The investigators found that the addition of PL to a GP solution had no measurable physiological or performance effects.

The study concluded that adding PolyLactate to a glucose polymer-based drink was not beneficial, i.e., it did not enhance endurance time during steady-state exercise; total carbohydrate was well controlled between trials such that subjects received the same amount of carbohydrate (7% solution, 0.3 g CHO/kg body weight) for each sub-maximal trial; subjects exercised at a sustainable energy expenditure of 70% VO₂max; the investigators did not conduct repeated trials with the two beverages, so reliability of exercise performance could not be assessed.

Limitations: The same caveat of very small sample size (n=5) applies. The exercise protocol was steady-state submaximal effort, which may not have been sufficiently taxing to distinguish differences in fuel substrate utilization pathways.

4.1.3 Azevedo et al. (2007) — Isotopic Tracer Study in Cyclists

A more methodologically sophisticated investigation was published in PLOS ONE in 2007, examining oxidation profiles of the constituent carbohydrates in CytoMax (containing PolyLactate™) versus a comparator sports drink using carbon isotope tracers. Exogenous carbohydrate oxidation was assessed in 6 male Category 1 and 2 cyclists who consumed CytoMax™ or a leading sports drink before and during continuous exercise; CytoMax contained lactate-polymer, fructose, glucose, and glucose polymer, while the comparator contained fructose and glucose; peak power output and VO₂ were 408 ± 13 W and 67.4 ± 3.2 ml O₂·kg⁻¹·min⁻¹; subjects performed 3 bouts with CytoMax and 2 with the comparator at 62% VO₂peak for 90 minutes, followed by high-intensity exercise (86% VO₂peak) to volitional fatigue.

High-intensity time to exhaustion after the continuous exercise bout was 25% longer with CytoMax than with the comparator (6.5 ± 0.8 vs. 5.2 ± 1.0 min, P < 0.05). The authors attributed this in part to the buffering properties of the PolyLactate component: the increased performance could be partially explained by the enhanced buffering capacity of PolyLactate; it had been demonstrated that there was increased bicarbonate and blood pH during exercise in subjects consuming a drink with PolyLactate as opposed to glucose polymer alone.

Limitations: The study involved only six subjects. Critically, the CytoMax formulation differed from the comparator in multiple carbohydrate components (not only the lactate-polymer but also fructose quantities and glucose polymer content), making it impossible to attribute the observed performance benefit specifically to the Alpha-L-Polylactate component rather than to the overall carbohydrate mixture. Neither this study nor the prior Fahey study utilized tracers to quantify metabolite fractional oxidation rates in a way that isolated the lactate contribution to the performance outcome. The PLOS ONE study did utilize tracers for oxidation rates, but the performance comparison was confounded by the multi-ingredient formula difference. Furthermore, the study was funded by or connected to the product manufacturer, as indicated by the industry-affiliation of the authors.

4.1.4 Subsequent Human Lactate Supplementation Research

Research on oral lactate supplementation more broadly (beyond the polylactate polymer formulation) has shown mixed results. Previous studies of oral lactate supplements in human exercise trials have yielded mixed results; direct comparisons are problematic as dosing, the nature of exercise, and primary outcomes appear inconsistent across studies; time to exhaustion during constant load (low-to-moderate intensity) exercise was unaffected by the addition of lactate to a carbohydrate sports drink.

A 2024 study published in Journal of Functional Morphology and Kinesiology examined 16 endurance-trained male cyclists. Sixteen endurance-trained male cyclists (VO₂max 59 ± 7 mL·kg⁻¹·min⁻¹) consumed 120 mg·kg⁻¹ body mass of lactate or a placebo 70 min prior to performing an exercise performance test comprising five repeated blocks of 1 km and 4 km time trials interspersed with 10 min of moderate-intensity exercise; blood acid-base balance, heart rate, perceived exertion, and gastro-intestinal tolerance were assessed; there was no effect of lactate supplementation on exercise performance (p = 0.320), despite a reduction in RPE (p = 0.012) and increases in [SID] (p = 0.026) and [HCO₃⁻] (p = 0.041). In addition, gastro-intestinal side effects were observed, but there was no effect on heart rate; lactate supplementation did not improve exercise performance, despite positive changes in acid-base balance and RPE.

A 2024 pilot randomized crossover clinical trial (Ewell et al., Nutrients) further assessed acute oral lactate supplementation during cycle ergometer exercise. Bicarbonate and pH were greater during three hours of constant load cycling following ingestion of a polylactate solution; time to exhaustion during short-duration, high-intensity treadmill exercise was barely extended (<2%) by high doses of lactate ingestion.

4.1.5 Overall Evidence Assessment for Exercise Performance

Subsequent research failed to show any additional endurance benefit when polylactate was added to carbohydrate feeding; the ingredient also turned out to be very expensive. The body of evidence, taken in aggregate, suggests that while polylactate/lactate supplementation consistently elevates blood pH and bicarbonate during exercise—consistent with the proposed buffering mechanism—translation of these acid-base changes into measurable improvements in exercise performance has not been reliably demonstrated in small, controlled human trials. The overall evidence base is preliminary, limited by very small sample sizes, inconsistent protocols, and, in some cases, confounded study designs.

4.2 Blood Glucose Maintenance During Exercise

One consistent finding across early polylactate studies was the maintenance of blood glucose at levels comparable to glucose polymer solutions. Fahey et al. found that in comparison to a glucose polymer, a PolyLactate-glucose polymer combination was able to maintain blood glucose at least as well as glucose polymer alone; this is likely due to the role of lactate in gluconeogenesis. This represents a secondary, plausible benefit—that lactate entering the liver could act as a gluconeogenic substrate, helping to sustain circulating glucose levels during extended exertion. However, this does not represent a unique advantage over isocaloric carbohydrate supplementation, as glucose polymers alone achieve comparable results.

4.3 Acid-Base Balance (Blood Buffering)

The most reproducible finding across studies is the elevation of blood bicarbonate and pH in subjects consuming polylactate compared to control or glucose polymer conditions. Bicarbonate and pH were greater during three hours of constant load cycling following ingestion of a polylactate solution. Fahey et al. found that PolyLactate resulted in greater bicarbonate concentration in the blood of their subjects; this greater bicarbonate concentration could have an implication on enhanced performance during high-intensity exercise.

The 2024 Bordoli et al. study confirmed the acid-base effect: there were significant increases in strong ion difference (SID) (p = 0.026) and HCO₃⁻ (p = 0.041) with lactate supplementation, despite no effect on performance. This dissociation between acid-base effects and performance outcomes remains unexplained and is a central unresolved question in the field.

4.4 Lactate as a Fuel: Oxidation Profile

Tracer evidence confirms that exogenous lactate supplied in the form of PolyLactate is oxidized rapidly and efficiently. ¹³CO₂ from the lactate tracer was significantly elevated above rest at 5 minutes of exercise and peaked at 15 minutes; by 60 minutes of exercise, ¹³CO₂ from the lactate tracer was 33% greater than from glucose and 36% greater than from fructose; cumulative recoveries of tracer during exercise were 92% ± 5.3% for lactate vs. 25% ± 4.0% for glucose. These oxidation data are consistent with the known physiology of lactate as a preferred fuel substrate in aerobically active muscle and cardiac tissue.

5. Body Systems and Health Areas

5.1 Skeletal Muscle Energetics and Recovery

The primary system targeted by Alpha-L-Polylactate is skeletal muscle energy metabolism. In the intracellular lactate shuttle, lactate produced in the cytoplasm of a muscle cell is transported directly into the mitochondria of the very same cell; once inside the mitochondria, lactate is converted back to pyruvate and used to fuel aerobic energy production; this internal recycling system allows a muscle cell to immediately reuse the lactate it generates. The polylactate formulation seeks to augment this natural process by delivering additional exogenous L-lactate for oxidation.

5.2 Cardiovascular System

During physical exertion or moderate intensity exercise, lactate released from working muscle and other tissue beds is the primary fuel source for the heart, exiting the muscles through monocarboxylate transport protein (MCT). The cardiac muscle is a major consumer of circulating lactate, and supplemental lactate from polylactate would be expected to enter this same metabolic pathway. Whether exogenous polylactate provides a measurable benefit to cardiac fuel availability during exercise in healthy athletes remains uninvestigated at the clinical level.

5.3 Brain and Central Nervous System

Both neurons and astrocytes (neuron-adjacent cells) have been shown to express MCT proteins, suggesting that the lactate shuttle may be involved in brain metabolism; astrocytes express MCT4, a low-affinity transporter for lactate suggesting its function is to export lactate produced by glycolysis; neurons express MCT2, a high-affinity transporter for lactate; it is hypothesized that astrocytes produce lactate which is then taken up by adjacent neurons and oxidized for fuel. The relevance of exogenous oral polylactate to brain energy metabolism in exercising humans has not been specifically studied.

5.4 Gastrointestinal System

Emerging research has explored the direct effects of oral lactate on the gastrointestinal tract, independent of its systemic metabolic roles. A study published in Clinical Nutrition (2022) found that oral lactate administration has a direct effect on the upper gastrointestinal tract, affecting gut hormone secretion, motility and appetite sensations which cannot be mediated through lactate in the systemic circulation alone; these data suggest that compounds rich in lactate may be useful in the treatment of metabolic disease. This effect was observed with intravenous-quality pharmaceutical-grade sodium lactate and has not been replicated specifically with the polylactate polymer formulation.

6. Dosage Forms and Reported Dosages

Alpha-L-Polylactate is not available as a standalone supplement and has been studied only as a component of multi-ingredient sports beverages. The following dosage details are derived from published experimental protocols and product formulation disclosures:

Fahey et al. (1991): A solution containing polylactate (PL: 80% polylactate, 20% sodium lactate, in 7% solution with water) was given 5 minutes before exercise and at 20-minute intervals during exercise.
Swensen et al. (1994): The GP/PL mixture was consumed at the rate of 0.3 g carbohydrate per kg of body weight in a 7% solution every 20 minutes; the mixture contained 6.25 g GP to 0.75 g PL per 100 ml of water.
Azevedo et al. (2007): Subjects performed exercise at 62% VO₂peak for 90 min, followed by high-intensity exercise to volitional fatigue; subjects consumed 250 ml fluid immediately before (−2 min) and every 15 min of cycling. The exact grams of PolyLactate per serving were not separately disclosed, as it was embedded within the commercial multi-carbohydrate formula.
Bordoli et al. (2024): Although this study used calcium lactate rather than the polylactate polymer, it is informative: participants consumed 120 mg·kg⁻¹ body mass of lactate (as calcium lactate) 70 minutes prior to exercise.
Cytomax product formulation: The overall ingredient composition includes CytoSport's unique complex carbohydrate blend including amylopectin starches and maltodextrin, crystalline fructose, dextrose, and Alpha-L-Polylactate (non-acidic L-lactate ionically bound to L-arginine), with the total carbohydrate content delivered per serving including these combined sources.

No official pharmacopeial or regulatory body (NIH ODS, EFSA, EMA, WHO) has established a recommended or tolerable upper intake level specifically for Alpha-L-Polylactate, as it is a proprietary trademarked ingredient that has not undergone formal monograph development through these channels.

7. Safety Considerations and Known Interactions

7.1 Gastrointestinal Adverse Effects

The most clearly documented and reproducible safety concern with polylactate and related lactate preparations is gastrointestinal distress. In Swensen et al.'s experimental conditions, PL as supplied by the manufacturer produced severe gastro-intestinal efflux in concentrations ≥ 2.5%; PL was tolerable in concentrations ≤ [lower threshold]. This is consistent with findings from broader lactate salt research. In addition to piloting sessions showing no increase in blood lactate concentrations in one study, there were several gastrointestinal side effects that accompanied the interventions; gastrointestinal issues are not uncommon with the consumption of sodium-bound supplements such as sodium bicarbonate or ketone salts; adding more water to decrease the high osmolarity of the solution was successful in reducing the severity of GI side effects though it was unable to eliminate them.

In experimental work with sodium lactate solutions, blood lactate barely increased while gastrointestinal distress was severe enough that vomiting occurred repeatedly during experiments; it is difficult to imagine athletes adopting a supplement strategy that regularly ends with nausea and vomiting before competition; the discomfort is likely caused by the very high osmolality of these lactate salt solutions. The polylactate polymer form was specifically developed to mitigate this problem by reducing osmolality through the use of larger molecules, and the evidence suggests partial success: lower concentrations of polylactate (<2.5%) appear tolerable.

The literature presents conflicting reports on gastro-intestinal disturbances associated with lactate supplementation, raising concerns about its suitability for prolonged exercise such as competitive cycling events.

7.2 Formulation Dependency

An important practical safety and efficacy consideration is that the tolerability and physiological effect of lactate-based preparations are highly sensitive to formulation characteristics. The contrast between studies highlights something critically important in this field: formulation matters enormously; the chemistry, pH, osmolarity, and purity of the solution appear to determine whether lactate supplementation is physiologically useful or simply intolerable; this challenge has led researchers to explore alternative delivery systems.

7.3 Blood Lactate and Bioavailability Considerations

One recent study found that oral sodium lactate did not reliably raise blood lactate concentrations, raising questions about systemic bioavailability in certain formulations. During piloting of an appetite study, researchers were unable to show that sodium lactate could increase blood lactate concentrations; five male participants completed 15 experimental sessions; oral sodium lactate ingestion did not increase blood lactate concentrations (Pre: 0.9 ± 0.2; 30 min: 1.2 ± 0.7; 45 min: 1.0 ± 0.5; 60 min: 0.9 ± 0.4 mmol·L⁻¹). It is not established whether the PolyLactate formulation, with its different molecular architecture and lower osmolality, overcomes this absorption limitation, and no direct head-to-head bioavailability comparisons between the polymer and simple lactate salts have been published in peer-reviewed sources accessible for this review.

7.4 Absence of Long-Term Safety Data

No long-term clinical safety trials have been published evaluating Alpha-L-Polylactate as an isolated compound. All available data are from short-duration exercise studies. No formal toxicological review, EFSA opinion, or NIH ODS fact sheet exists for this proprietary ingredient. The constituent L-lactate, as a normal human metabolite, is generally considered physiologically safe at the concentrations produced endogenously during exercise, but formal safety thresholds for repeated supplemental use have not been established.

7.5 Drug and Nutrient Interactions

No peer-reviewed clinical or pharmacological literature documenting specific drug-drug or drug-nutrient interactions with Alpha-L-Polylactate has been identified. The broader concern with high-osmolality solutions is that their ingestion can draw fluid into the gut lumen, potentially impairing absorption of co-ingested compounds. Administration of hyperosmotic solution directly into the gastrointestinal tract significantly increased the GI fluid volume, owing to secretion of water into the lumen. This effect—relevant at high concentrations of lactate salts—would be expected to be attenuated at the lower osmolality of the polylactate polymer formulation.

8. Summary of Evidence Quality

The totality of published peer-reviewed evidence on Alpha-L-Polylactate and its polylactate precursor is sparse, dated, and methodologically limited. The landmark human studies (Fahey 1991; Swensen 1994; Azevedo 2007) each involved five to six subjects. No large-scale randomized controlled trials, no systematic reviews, and no meta-analyses specifically examining this ingredient exist in the literature. Mechanistic evidence is more robust: the lactate shuttle hypothesis is well-supported by decades of basic science, and the buffering chemistry of the lactate anion is physically established. However, the translation of these mechanistic findings into reliable, reproducible ergogenic outcomes in human subjects has not been demonstrated at a standard of evidence that would meet criteria for a well-supported health or performance claim under regulatory frameworks such as those applied by EFSA or the U.S. Federal Trade Commission. The ingredient's commercial development substantially outpaced its clinical validation.